Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2014; 20(11): 2876-2887
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2876
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2876
Table 2 Antiviral therapies for hepatitis C virus-related liver cirrhosis
Antiviral therapy | Number of treated patients | SVR rate | Decompensation1 | HCC1 | Mortality1 | Severe AE rate2 | Ref. |
IFN-based therapy aiming at SVR | |||||||
IFN monotherapy | 271 | 15.1% for genotype 1; 47.2% for others | 0.65 (0.31) | 0.54 (0.05) | [32] | ||
IFN + RBV | 132 | 30.3% for genotype 1b; 80.0% for others | (0.28) | 12.1% | [33] | ||
Pegylated IFN + RBV | 57 | 24.2% for genotype 1; 70.8% for others | 10.5% | [26] | |||
87 | 20.5% for genotype 1/4; 72.1% for genotype 2/3 | 25.0% | [28] | ||||
568 | 24.4% for genotype 1; 54.9% for others | 29.6% | [36] | ||||
Pegylated IFN + RBV + boceprevir | 39 (all genotype 1) | 59.0% | [79] | ||||
Pegylated IFN + RBV + telaprevir | 21 (all genotype 1) | 61.9% | [24] | ||||
Pegylated IFN + RBV + simeprevir | 83 (all genotype 1) | 70%-73% for relapsers; 15%-82% for partial responders; 31%-46% for null responders | [82] | ||||
Pegylated IFN + RBV + mericitabine | 21 (genotype 1/4) | 38.1% | [83] | ||||
IFN-based therapy after treatment for HCC | |||||||
IFN monotherapy | 76 (pure HCV, 42) | 0.303 | 0% | [74] | |||
Pegylated IFN maintenance therapy | 427 | 0.45 | [57] | ||||
311 (portal hypertension, 39) | 0.254 | 17% | [56] | ||||
Faldaprevir + deleobuvir + RBV | 34 (all genotype 1) | 57% in patients treated thrice daily; 54% in patients treated twice daily | [85] |
- Citation: Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol 2014; 20(11): 2876-2887
- URL: https://www.wjgnet.com/1007-9327/full/v20/i11/2876.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i11.2876